Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Interest & Investment Income (2016 - 2025)

Altimmune (ALT) has disclosed Interest & Investment Income for 14 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income rose 27.02% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.7 million, a 21.22% decrease, with the full-year FY2024 number at $8.1 million, up 9.84% from a year prior.
  • Interest & Investment Income was $2.4 million for Q3 2025 at Altimmune, up from $1.1 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.4 million in Q3 2025 to a low of $13000.0 in Q3 2021.
  • A 5-year average of $1.2 million and a median of $1.5 million in 2025 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: crashed 72.29% in 2021, then soared 8000.0% in 2022.
  • Altimmune's Interest & Investment Income stood at $115153.0 in 2021, then surged by 1174.83% to $1.5 million in 2022, then surged by 33.79% to $2.0 million in 2023, then decreased by 20.11% to $1.6 million in 2024, then skyrocketed by 54.62% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Interest & Investment Income are $2.4 million (Q3 2025), $1.1 million (Q2 2025), and $1.5 million (Q1 2025).